Cannabis News

The Company's latest U.S. patent is for the Acetylation of Cannabinoids, protecting the production of a CBD-derived prodrug with potential applications in the pharmaceutical industry.

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) ("Nextleaf", "OILS", or the "Company"), Canada's most innovative cannabis extractor, announced today that the United States Patent and Trademark Office has granted the Company a second patent for the acetylation of cannabinoids. More specifically, the patent covers a process for acetylating cannabidiol ("CBD"), and subsequent refinement of CBO-O-Acetate.

The Company owns a portfolio of 10 issued U.S. patents for extraction, purification, and delivery of cannabinoids, along with a 100% success rate obtaining issued patents from its pending patent applications, compared to less than 50% for life science companiesI.

"We expect the results of the 2020 U.S. elections will have a transformational effect on the future of cannabis legalization in the United States," stated Paul Pedersen, CEO of Nextleaf Solutions. "With the second largest patent portfolio of any cannabis company, Nextleaf has the type of robust intellectual property that draws attention from pharmaceutical companies anticipating the U.S. federal legalization of cannabinoids."

Nextleaf's patented process to produce CBD-O-Acetate enables the standardization of a more potent analog of CBD, an alternative option to experience the unique medicinal benefits associated with targeted drug delivery. Prodrugs utilize various physical and chemical modifications to improve features of active drugs. Maintaining the integrity of the molecule and its ability to deliver drugs to precisely targeted areas in the body may increase efficacy for desired outcomes.

The Company believes an orally consumable CBD metabolic prodrug produced under its patented process for acetylating cannabidiol will enhance the therapeutic potency of CBD.

OILS was granted a U.S. patent in February for the acetylation of delta 9-tetrahydrocannabinol ("THC"), and subsequent refinement of THC-O-Acetate.

"With this second U.S. patent for acetylation of cannabinoids, we are able to efficiently modify and potentially improve upon the medicinal properties of a natural product that has been in use for thousands of years," stated Ryan Ko, Chief Technical Officer.

The Company has commenced a search for commercialization partners of its cannabinoid acetylation patents, with a specific focus on pharmaceutical companies seeking novel cannabinoid-derived products for clinical trials, and turnkey pharmaceutical production.

About Nextleaf®

OILS is Canada's most innovative cannabis extractor, developing technology for extracting and distilling cannabinoids. OILS wholesales THC and CBD oils and provides extraction services through its wholly owned subsidiary Nextleaf Labs Ltd., a Health Canada licensed processor. The Company owns a portfolio of over 50 issued patents and over 50 pending patents for the extraction, purification, and delivery of cannabinoids. The Company's proprietary closed-loop extraction plant in Metro Vancouver has a design capacity to process 600 kg per day of dried cannabis biomass into distilled oils.

Nextleaf Solutions trades as OILS on the Canadian Securities Exchange, OILFF on the OTCQB Market in the United States, and L0MA on the Frankfurt Stock Exchange.

Follow OILS across social media platforms: Twitter, LinkedIn, Facebook, and Instagram.

www.nextleafsolutions.com

For more information please contact:
Jason McBride
604-283-2301 (ext. 219)
investors@nextleafsolutions.com

On behalf of the Board of Directors of OILS,

Paul Pedersen, CEO

Certain statements contained in this press release constitute "forward-looking statements". All statements other than statements of historical fact contained in this press release, including, without limitation, those regarding the Company's ability to capitalize on its IP portfolio,the Company's strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words "believe", "expect", "aim", "intend", "plan", "continue", "will", "may", "would", "anticipate", "estimate", "forecast", "predict", "project", "seek", "should" or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only the Company's expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. Additional factors that could cause actual results, performance or achievements to differ materially include, but are not limited to the risk factors discussed in the Company's MD&A for the most recent fiscal period. Management provides forward-looking statements because it believes they provide useful information to investors when considering their investment objectives and cautions investors not to place undue reliance on forward-looking information. Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company. These forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as required by law. The CSE has not reviewed or approved the contents of this press release.

IMichael Carley, Deepak Hegde & Alan Marco, What is the Probability of Receiving a U.S. Patent?, 17 Yale J.L. & Tech (2015). Available at: https://digitalcommons.law.yale.edu/yjolt/vol17/iss1/5

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/67544

News Provided by Newsfile via QuoteMedia

Trulieve Opening Medical Marijuana Dispensary in Auburndale

New dispensary expands patient access to medical cannabis; grand opening specials available

9 p.m. from Monday through Saturday and 10 a.m8 p.m. on Sunday .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Hygrovest

HGV Investment Portfolio Report July 2022

HGV Limited (ASX: HGV) ("HGV”)is an Australian-listed specialist investment company which concentrates on producing capital growth for shareholders over the medium term from investments in listed and unlisted equities and other financial assets.

Keep reading...Show less
VIDEO — HEXO CEO: Aggressive Pursuit of Clean Balance Sheet Has Reset Company

VIDEO — HEXO CEO: Aggressive Pursuit of Clean Balance Sheet Has Reset Company

It’s been a seriously difficult period for Canadian cannabis operators over the past few years, with volatility prevailing as the status quo for companies in the market.

Charlie Bowman, president and CEO of HEXO (NASDAQ:HEXO,TSX:HEXO), understands that, and that’s why his first order of business after taking the helm at the company was to clean up its finances. He sees a better path ahead for HEXO now that it has restructured its assets and had its debt purchased by a fellow Canadian producer.

Bowman spoke at length with the Investing News Network (INN) about the downturn in Canadian cannabis stocks, HEXO’s NASDAQ listing status and its partnership with Tilray Brands (NASDAQ:TLRY,TSX:TLRY).

Keep reading...Show less
Avicanna Reports Q2 2022 Financial Statement

Avicanna Reports Q2 2022 Financial Statement

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS

Avicanna Inc. (" Avicanna " or the " Company ") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce the filing of its interim financial statements for the three-month period ending June 30, 2022 (" Q2 2022 ").

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Limited-Edition Pumpkin Spice CBD Wellness Gummies Arrive Just in Time for Fall As Martha Stewart CBD Expands Portfolio

New, classic fall flavor joins brand's best-selling lineup of CBD products

Today, Martha Stewart CBD unveiled the latest flavor in its CBD portfolio Pumpkin Spice CBD Wellness Gummies. Inspired by the most recognized flavor of the fall, these new gummies tap into the spirit of the season and are the perfect addition to consumers' favorite fall activities. These limited-edition gummies continue the expansion of the Martha Stewart CBD gummies lineup, which features some of the brands most popular items and flavors, including the Tropical Medley CBD Wellness Gummies™ and Harvest Medley CBD Wellness Gummies™.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
The Greenrose Holding Company Postpones Second Quarter 2022 Conference Call, Originally Scheduled for August 15, 2022 at 5:00 p.m. ET

The Greenrose Holding Company Postpones Second Quarter 2022 Conference Call, Originally Scheduled for August 15, 2022 at 5:00 p.m. ET

The Greenrose Holding Company Inc. (OTC: GNRS, GNRSW) ("Greenrose" or the "Company"), a multi-state grower and producer of cannabis brands and products announced that it will be postponing its scheduled conference call on Monday, August 15, 2022, at 5:00 p.m. Eastern time to discuss its results for the second quarter ended June 30, 2022.

Greenrose is committed to reporting its second quarter 2022 financial results and providing an update on timing for the rescheduled conference call as soon as practicable. The Company expects to issue revised call details once confirmed.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×